Engineered immune cells take on HPV cancers
NCT ID NCT02858310
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tested a new therapy for cancers caused by HPV-16, such as cervical, anal, and throat cancers. Researchers took patients' white blood cells, genetically engineered them to recognize a protein called E7 found in HPV cancer cells, and infused them back. Patients also received chemotherapy and supportive drugs. The study aimed to find a safe dose and see if the treatment could shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- E7 T cell receptor (TCR) cells
- What this could lead to
- If successful, this could offer a new treatment option for people with HPV-related cancers that have not responded to standard therapy.
- What could go wrong
- This is an early-phase trial, so the treatment may not work for everyone. Side effects can be serious, including reactions to the cell infusion and chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immunotherapy drug boost the power of chemoradiation against anal cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an antiviral make radiation more effective against cervical cancer?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a Two-Antibody combo outsmart advanced cancer?